These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21160989)

  • 1. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report.
    Niazi MA; Azhar A; Tufail K; Feyssa EL; Penny SF; McGregory M; Araya V; Ortiz JA
    World J Hepatol; 2010 Apr; 2(4):162-6. PubMed ID: 21160989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report.
    Lahbabi M; Ghissassi M; Belahcen F; Ibrahimi SA; Aqodad N
    J Med Case Rep; 2012 Sep; 6():278. PubMed ID: 22947101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
    Lee MY; Cho H; Kim YM; Lee JS
    Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.
    Khiani V; Kelly T; Shibli A; Jensen D; Mohanty SR
    World J Gastroenterol; 2008 Jan; 14(2):318-21. PubMed ID: 18186575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C].
    Zhang HF; Yang XJ; Zhu SS; Dong Y; Chen DW; Jia WZ; Xu ZQ; Mao YL; Tang HM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):185-7. PubMed ID: 16027794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C.
    Nishio K; Konndo T; Okada S; Enchi M
    World J Hepatol; 2010 Sep; 2(9):358-61. PubMed ID: 21161021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
    Bosques-Padilla F; Trejo-Estrada R; Campollo-Rivas O; Cortez-Hernández C; Dehesa-Violante M; Maldonado-Garza H; Pérez-Gómez R; Cabrera-Valdespino A
    Ann Hepatol; 2003; 2(3):135-9. PubMed ID: 15115965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.
    Brixner DI; Ye X; Chu TC; Blumentals WA; Hassanein TI
    Am J Health Syst Pharm; 2009 Dec; 66(24):2171-8. PubMed ID: 19966085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome during treatment with interferon alpha for hepatitis B.
    Boz C; Ozmenoglu M; Aktoz G; Velioglu S; Alioglu Z
    J Clin Neurosci; 2004 Jun; 11(5):523-5. PubMed ID: 15177399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.
    Jabbari H; Fakharzadeh E; Merat S; Zamini H; Sharifi AH
    Arch Iran Med; 2011 May; 14(3):204-5. PubMed ID: 21529112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.